Author

Rhys Williams

Observed name: Williams, Rhys

Institution: BeOne Medicines (Switzerland)

Observed institution: BeOne Medicines (Switzerland)

OpenAlex ID: A5123511684

A Meta-analysis Investigating Response Rates with Continuous Bruton Tyrosine Kinase Inhibitor Monotherapies in the Treatment of B Cell Lymphomas

2026 · Pier Luigi Zinzani, Rhys Williams, et al. · Oncology and Therapy · 1

An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma

2026 · Toby A. Eyre, Leyla Mohseninejad, et al. · Figshare

An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma

2026 · Toby A. Eyre, Leyla Mohseninejad, et al. · Journal of Medical Economics

Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia

2026 · Jing-Zhou Hou, Rushir Choksi, et al. · Future Oncology

Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up

2026 · Adis Journals on behalf of, Shadman, Mazyar, et al. · Figshare

Real-world impact of atrial fibrillation (AFib) on cardiovascular (CV) outcomes and healthcare resource utilization (HCRU) in patients with chronic lymphocytic leukemia (CLL).

2026 · Michael Fradley, Daniel Addison, et al. · Journal of Clinical Oncology

Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia

2026 · Mazyar Shadman, Asher Chanan-Khan, et al. · Future Oncology

Prolonged progression-free survival with zanubrutinib in relapsed/refractory CLL: an indirect treatment comparison versus other BTK inhibitors using multilevel network meta-regression

2026 · Mazyar Shadman, Walter Bouwmeester, et al. · Journal of Medical Economics

Prolonged progression-free survival with zanubrutinib in relapsed/refractory CLL: an indirect treatment comparison versus other BTK inhibitors using multilevel network meta-regression

2026 · Shadman, Mazyar, Bouwmeester, Walter, et al. · Figshare

Works count: 9

Citation count: 1

H-index: 1

I10-index: